申请人:Topivert Pharma Limited
公开号:US20140296271A1
公开(公告)日:2014-10-02
There is provided a compound of formula I,
which compound has antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases, e.g., Src and Lck) and has use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
提供了一种化合物I,该化合物具有抗炎活性(例如通过抑制p38丝裂原活化蛋白激酶酶家族的一个或多个成员、Syk激酶和酪氨酸激酶Src和Lck等家族成员之一),并且可用于治疗,包括在药物组合中,特别是用于治疗炎症性疾病,包括肺部、眼睛和肠道的炎症性疾病。